Erythropoietin plus methylprednisolone versus methylprednisolone plus placebo in the treatment of acute spinal cord injury: A pilot study

A randomized clinical trial on comparison of erythropoietin plus methylprednisolone versus methylprednisolone plus placebo in the improvement of neurologic outcome after acute spinal cord injury

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000602224

Enrollment

Registered

2009-07-21

Start date

2006-09-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study aimed to evaluate the effectiveness of intravenous human recombinnant erythropoietin plus methylprednisolone versus methylprednisolone alone to improve neurologic outcome during a six month follow-up after traumatic cord injury

Interventions

Methylprednisolone sodium succinate intravenously 30 mg/kg on admission and 5.4 mg/kg every hour till 23 hours(if admitted within 3 hours after injury) and till 47 hours (if admitted between 3-6 hours after injury) plus intravenous injection of 500 unit/kg of recombinant human erythropoietin in 500 ml normal saline on admission and another 500 unit/kg of recombinant human erythropoietin in 500 ml normal saline 24 hours later

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

Spinal cord injury presenting to emergency department within 6 hours after injury

Exclusion criteria

only qauda equina or nerve root involvement

Outcome results